In this review, we explore the most common causes of resistance to anti-PD-1/PD-L1 immunotherapy in GBM, as well as possible ways of overcoming the immunosuppressive TME, primarily through the exploitation of combination therapy. Here, CD274 is linked to glioblastoma.